Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

被引：6

作者：

Menard, Timothe ^{[1
]}

Young, Kyle ^{[2
]}

Siegel, Laura ^{[3
]}

Emerson, Jennifer ^{[4
]}

Studt, Robert ^{[5
]}

Sidor, Leslie ^{[6
]}

机构：

[1] F Hoffmann La Roche & Cie AG, CH-4070 Basel, Switzerland

[2] Merck & Co Inc, Kenilworth, NJ USA

[3] GlaxoSmithKline GSK, Collegeville, PA USA

[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[5] Johnson & Johnson, Spring House, PA USA

[6] Biogen, Cambridge, MA USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2021年 / 10卷 / 08期

关键词：

D O I：

10.1002/psp4.12677

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.

引用

页码：799 / 803

页数：5

共 4 条

[1] An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium
Koneswarakantha, Bjoern
Adyanthaya, Ronojit
Emerson, Jennifer
Collin, Frederik
Keller, Annett
Mattheus, Michaela
Spyroglou, Ioannis
Donevska, Sandra
Menard, Timothe
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (04) : 591 - 599
[2] Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression
Cosgrove, Lisa
Krimsky, Sheldon
Wheeler, Emily E.
Peters, Shannon M.
Brodt, Madeline
Shaughnessy, Allen F.
ACCOUNTABILITY IN RESEARCH-POLICIES AND QUALITY ASSURANCE, 2017, 24 (02): : 99 - 115
[3] Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group
Rollison, Helen E.
Mitra, Pallabi
Chanteux, Hugues
Fang, Zhizhou
Liang, Xiaomin
Park, Seong Hee
Costales, Chester
Hanna, Imad
Thakkar, Nilay
Vergis, James M.
Bow, Daniel A. J.
Hillgren, Kathleen M.
Brumm, Jochen
Chu, Xiaoyan
Hop, Cornelis E. C. A.
Lai, Yurong
Li, Cindy Yanfei
Mahar, Kelly M.
Salphati, Laurent
Sane, Rucha
Shen, Hong
Taskar, Kunal
Taub, Mitchell
Tohyama, Kimio
Xu, Christine
Fenner, Katherine S.
DRUG METABOLISM AND DISPOSITION, 2024, 52 (07) : 582 - 596
[4] Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group-Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future
Krishna, Rajesh
Sebastien, Bernard
Corriol-Rohou, Solange
Cheung, S. Y. Amy
Liu, Jing
Suryawanshi, Satyendra
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (06) : 1433 - 1441

← 1 →